Proteon Therapeutics Competitors

Proteon Therapeutics (NASDAQ:PRTO) and Vaxcyte (NASDAQ:PCVX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Proteon Therapeutics and Vaxcyte's net margins, return on equity and return on assets.

Insider and Institutional Ownership

23.0% of Proteon Therapeutics shares are owned by institutional investors. Comparatively, 74.1% of Vaxcyte shares are owned by institutional investors. 45.7% of Proteon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Proteon Therapeutics and Vaxcyte's top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Proteon Therapeutics and Vaxcyte, as provided by MarketBeat.

Vaxcyte has a consensus target price of $48.00, indicating a potential upside of 103.22%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than Proteon Therapeutics.

Summary

Vaxcyte beats Proteon Therapeutics on 4 of the 6 factors compared between the two stocks.

Proteon Therapeutics (NASDAQ:PRTO) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.

Volatility & Risk

Proteon Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.

Valuation and Earnings

This table compares Proteon Therapeutics and Coherus BioSciences' revenue, earnings per share and valuation.

Coherus BioSciences has higher revenue and earnings than Proteon Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

23.0% of Proteon Therapeutics shares are held by institutional investors. 45.7% of Proteon Therapeutics shares are held by insiders. Comparatively, 15.9% of Coherus BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Proteon Therapeutics and Coherus BioSciences' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Proteon Therapeutics and Coherus BioSciences, as provided by MarketBeat.com.

Coherus BioSciences has a consensus price target of $27.8571, suggesting a potential upside of 82.73%. Given Coherus BioSciences' higher probable upside, analysts clearly believe Coherus BioSciences is more favorable than Proteon Therapeutics.

Summary

Coherus BioSciences beats Proteon Therapeutics on 10 of the 12 factors compared between the two stocks.

Mesoblast (NASDAQ:MESO) and Proteon Therapeutics (NASDAQ:PRTO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Insider & Institutional Ownership

2.8% of Mesoblast shares are held by institutional investors. Comparatively, 23.0% of Proteon Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 45.7% of Proteon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Mesoblast has a beta of 3.71, meaning that its share price is 271% more volatile than the S&P 500. Comparatively, Proteon Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Mesoblast and Proteon Therapeutics, as reported by MarketBeat.com.

Mesoblast currently has a consensus price target of $14.55, indicating a potential upside of 58.50%. Given Mesoblast's higher possible upside, equities research analysts plainly believe Mesoblast is more favorable than Proteon Therapeutics.

Valuation & Earnings

This table compares Mesoblast and Proteon Therapeutics' revenue, earnings per share and valuation.

Proteon Therapeutics has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Proteon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mesoblast and Proteon Therapeutics' net margins, return on equity and return on assets.

Summary

Mesoblast beats Proteon Therapeutics on 7 of the 12 factors compared between the two stocks.

Proteon Therapeutics (NASDAQ:PRTO) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for Proteon Therapeutics and Cortexyme, as provided by MarketBeat.

Cortexyme has a consensus price target of $50.00, suggesting a potential upside of 37.48%. Given Cortexyme's higher possible upside, analysts clearly believe Cortexyme is more favorable than Proteon Therapeutics.

Profitability

This table compares Proteon Therapeutics and Cortexyme's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Proteon Therapeutics and Cortexyme's top-line revenue, earnings per share and valuation.

Cortexyme is trading at a lower price-to-earnings ratio than Proteon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

23.0% of Proteon Therapeutics shares are held by institutional investors. Comparatively, 55.5% of Cortexyme shares are held by institutional investors. 45.7% of Proteon Therapeutics shares are held by insiders. Comparatively, 19.8% of Cortexyme shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Proteon Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Cortexyme has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

Adverum Biotechnologies (NASDAQ:ADVM) and Proteon Therapeutics (NASDAQ:PRTO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

97.4% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 23.0% of Proteon Therapeutics shares are held by institutional investors. 12.4% of Adverum Biotechnologies shares are held by insiders. Comparatively, 45.7% of Proteon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Adverum Biotechnologies and Proteon Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Adverum Biotechnologies and Proteon Therapeutics' revenue, earnings per share and valuation.

Proteon Therapeutics has lower revenue, but higher earnings than Adverum Biotechnologies. Proteon Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Adverum Biotechnologies and Proteon Therapeutics, as provided by MarketBeat.

Adverum Biotechnologies presently has a consensus target price of $23.50, suggesting a potential upside of 114.42%. Given Adverum Biotechnologies' higher probable upside, analysts clearly believe Adverum Biotechnologies is more favorable than Proteon Therapeutics.

Risk and Volatility

Adverum Biotechnologies has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500. Comparatively, Proteon Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

Summary

Adverum Biotechnologies beats Proteon Therapeutics on 8 of the 11 factors compared between the two stocks.

Inhibrx (NASDAQ:INBX) and Proteon Therapeutics (NASDAQ:PRTO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Inhibrx and Proteon Therapeutics' net margins, return on equity and return on assets.

Insider and Institutional Ownership

36.6% of Inhibrx shares are held by institutional investors. Comparatively, 23.0% of Proteon Therapeutics shares are held by institutional investors. 45.7% of Proteon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Inhibrx and Proteon Therapeutics' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Inhibrx and Proteon Therapeutics, as provided by MarketBeat.

Inhibrx presently has a consensus price target of $34.6667, indicating a potential upside of 30.52%. Given Inhibrx's higher possible upside, research analysts clearly believe Inhibrx is more favorable than Proteon Therapeutics.

Summary

Inhibrx beats Proteon Therapeutics on 4 of the 5 factors compared between the two stocks.